Come and join us across the globe
Daniel Vela-Duarte and Raul Nogueira break down the results of the SUMMIT Max trial, published in May 2025. This randomized study compared the super large bore HiPoint® Reperfusion System by Route 92 Medical to the Stryker Vecta System for aspiration thrombectomy in anterior circulation large vessel occlusion (LVO). SUMMIT MAX is the first randomized controlled trial to compare the safety and efficacy between two aspiration thrombectomy devices.
The 088 HiPoint® Reperfusion System was shown to have equivalent safety and more efficacy compared to the 0.7x systems in achieving successful reperfusion; reinforcing the viability of larger-bore catheters in modern mechanical thrombectomy.
Sponsored by Route 92
Trial available here